Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Arkenau, H. T.
Right arrow Articles by Porschen, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arkenau, H. T.
Right arrow Articles by Porschen, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:395-399, 2003
© 2003 European Society for Medical Oncology

Original Paper

5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial

H. T. Arkenau1, A. Bermann2, K. Rettig3, G. Strohmeyer4 and R. Porschen On behalf of the Arbeitsgemeinschaft Gastrointestinale Onkologie1,+

1 Clinic of Internal Medicine, Central Hospital Bremen East, Bremen; 2 Department of Internal Medicine I, University of Tübingen, Tübingen; 3 Department of Gastroenterology, University of Düsseldorf, Düsseldorf; 4 Society for Evaluation and Quality Control in Medicine (GEM), Meerbusch, Germany

Received 2 May 2002; revised 16 August 2002; accepted 11 September 2002

Background:

Adjuvant postoperative treatment with 5-fluorouracil (5-FU) and leucovorin in curatively resected stage III colon cancer significantly reduces the risk of cancer recurrences and improves survival. The impact of 5-FU plus leucovorin on survival and tumor recurrence was analyzed in a long-term follow-up study in comparison with the effects of 5-FU plus levamisole in the prospective multicenter trial adjCCA-01.

Patients and methods:

Patients with a curatively resected stage III (International Union Against Cancer) colon cancer were stratified according to tumor, node and grading category and randomly assigned to receive one of the two adjuvant treatment schemes: 5-FU 400 mg/m2 body surface area intravenously in the first chemotherapy course, then 450 mg/m2 x 5 days, plus leucovorin 100 mg/m2, 12 cycles (arm A), or 5-FU plus levamisole (Moertel scheme; arm B).

Results:

Six hundred and eighty (96.9%) of 702 patients enrolled into this study were eligible. To date, 261 patients have died, 117 on arm A and 144 on arm B (P = 0.007). After a median follow-up time of 82 months, the 5-FU plus leucovorin combination significantly improved disease-free survival [79.8 months in arm A versus 69.3 months in arm B (P = 0.012)] and significantly increased median overall survival (88.9 months in arm A versus 78.6 months in arm B; P = 0.003). Adjuvant treatment with 5-FU plus levamisole as well as 5-FU plus leucovorin was generally well tolerated; only a minority of patients experienced grade 3 and 4 toxicities.

Conclusions:

After curative resection of a stage III colon cancer, adjuvant treatment with 5-FU plus leucovorin is generally well tolerated. This long-term follow-up study demonstrates that adjuvant treatment with 5-FU plus leucovorin given for 12 cycles is significantly more effective than 5-FU plus levamisole (Moertel scheme) in reducing tumor relapse and improving survival.

Key words: adjuvant chemotherapy, colon cancer, 5-fluorouracil, leucovorin, levamisole


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
I. M. Hennig, J. D. Naik, S. Brown, A. Szubert, D. A. Anthoney, D. P. Jackson, A. M. Melcher, S. M. Crawford, C. Bradley, J. M.B. Brown, et al.
Severe Sequence-Specific Toxicity When Capecitabine Is Given After Fluorouracil and Leucovorin
J. Clin. Oncol., July 10, 2008; 26(20): 3411 - 3417.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. J. A. Punt, M. Buyse, C.-H. Kohne, P. Hohenberger, R. Labianca, H. J. Schmoll, L. Pahlman, A. Sobrero, and J.-Y. Douillard
Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials
J Natl Cancer Inst, July 4, 2007; 99(13): 998 - 1003.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. Twelves, A. Wong, M. P. Nowacki, M. Abt, H. Burris III, A. Carrato, J. Cassidy, A. Cervantes, J. Fagerberg, V. Georgoulias, et al.
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
N. Engl. J. Med., June 30, 2005; 352(26): 2696 - 2704.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Nakamura, S. Miyamoto, H. Maeda, S.-c. Zhang, T. Sangai, G. Ishii, T. Hasebe, Y. Endoh, N. Saito, M. Asaka, et al.
Low Levels of Insulin-Like Growth Factor Type 1 Receptor Expression at Cancer Cell Membrane Predict Liver Metastasis in Dukes' C Human Colorectal Cancers
Clin. Cancer Res., December 15, 2004; 10(24): 8434 - 8441.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
W. Scheithauer, J. McKendrick, S. Begbie, M. Borner, W. I. Burns, H. A. Burris, J. Cassidy, D. Jodrell, P. Koralewski, E. L. Levine, et al.
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
Ann. Onc., December 1, 2003; 14(12): 1735 - 1743.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.